Prime Medicine, Inc.
PRME
$3.27
-$0.03-0.91%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.12M | -46.08M | -50.58M | -52.59M | -51.89M |
| Total Depreciation and Amortization | 1.86M | 1.88M | 1.88M | 1.86M | 1.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.06M | 5.79M | 13.05M | 8.77M | 8.99M |
| Change in Net Operating Assets | -2.50M | 1.16M | 609.00K | 548.00K | -7.65M |
| Cash from Operations | -42.71M | -37.26M | -35.04M | -41.41M | -48.86M |
| Capital Expenditure | -214.00K | -290.00K | -247.00K | -1.57M | -2.42M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.61M | 28.62M | -91.88M | 4.34M | -45.32M |
| Cash from Investing | 43.39M | 28.33M | -92.12M | 2.77M | -47.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 393.00K | 562.00K | 138.75M | 197.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 6.00M | 0.00 | 6.00M |
| Cash from Financing | 393.00K | 562.00K | 144.75M | 197.00K | 6.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.07M | -8.36M | 17.59M | -38.44M | -90.60M |